Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jul 1;11(13):3820.
doi: 10.3390/jcm11133820.

Use of Positron Emission Tomography for Pregnancy-Associated Cancer Assessment: A Review

Giulia Parpinel  1 , Maria Elena Laudani  1 , Francesca Paola Giunta  2 , Chiara Germano  3 , Paolo Zola  1 , Bianca Masturzo  3
Affiliations
Review

Use of Positron Emission Tomography for Pregnancy-Associated Cancer Assessment: A Review

Giulia Parpinel et al. J Clin Med. .

Abstract

Background. Positron emission tomography (PET) has proven clinical utility both in the initial and relapse staging phase, but this technique is controversial during pregnancy. The objective of this review is to provide a compendium of available information on the use of PET during pregnancy. Materials and methods. A systematic literature review was conducted from 1 January 2004 until 20 May 2021. A total of 4 small series and 9 case reports consisting of 25 cases were selected. Results. During the first trimester, the fetus is most sensitive to ionization damage, so lower doses are recommended (2.6E-02 mGy/MBq). Fetal-effective doses are higher in this period and the average fetal dose (4.06 ± 3.22 mGy) remains significantly below the threshold for deterministic effects. During the second and third trimesters, recommended doses are higher (1.4E-02 mGy/MBq at 6 months, and 6.9E-03 mGy/MBq at 9 months of gestation). 18F-FDG activity was distributed to the whole fetus with a prevalence of myocardial tissue in seven cases. The use of special precautions, such as PET-magnetic resonance (MR) and urinary bladder catheterization, reduces the amount of radioactive tracer. Breastfeeding interruption is not recommended. Conclusions. 18F-FDG PET is not contraindicated in pregnancy, but multidisciplinary discussion is necessary and strict precautions are recommended.

Keywords: 18F-FDG; cancer; dosimetry; positron emission tomography; pregnancy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Amant F., Van Calsteren K., Halaska M.J., Berveiller P., Boere I.A., Cardonick E., Fruscio R., Fumagalli M., Hasenburg A., Johansson A.L.V. Gynecologic cancers in pregnancy. Int. J. Gynecol. Cancer. 2009;19:S1–S12. doi: 10.1111/IGC.0b013e3181a1d0ec. - DOI - PubMed
    1. Masturzo B., Parpinel G., Macchi C., Paracchini S., Baima Poma C., Danna P., Pagliardini G., Zola P. Impact of cancer in the management of delivery: 10 years of variations. J. Matern. Fetal Neonatal Med. 2020;33:2006–2011. doi: 10.1080/14767058.2018.1536117. - DOI - PubMed
    1. Zanotti-Fregonara P., Champion C., Trebossen R., Trébossen R., Maroy R., Devaux J., Hindié E. Estimation of the beta1 dose to the embryo resulting from 18F-FDG administration during early pregnancy. J. Nucl. Med. 2008;49:679–682. doi: 10.2967/jnumed.107.048900. - DOI - PubMed
    1. Zanotti-Fregonara P., Jan S., Taieb D., Cammilleri S., Trébossen R., Hindié E., Mundler O. Absorbed 18F-FDG dose to the fetus during early pregnancy. J. Nucl. Med. 2010;51:803–805. doi: 10.2967/jnumed.109.071878. - DOI - PubMed
    1. Benveniste H., Fowler J.S., Rooney W.D., Moller D.H., Backus W.W., Warner D.A., Carter P., King P., Scharf B., Alexoff D.A., et al. Maternal-fetal in vivo imaging: A combined PET and MRI study. J. Nucl. Med. 2003;44:1522–1530. - PubMed

LinkOut - more resources